[1]刘鑫,王一星,李冠宏,等.Cytokeratin和CD133在肺腺癌患者外周血中的联合检测及临床病理分析[J].第三军医大学学报,2017,39(20):2004-2009.
 LIU Xin,WANG Yixing,LI Guanhong,et al.Combined detection and clinical pathological analysis of peripheral blood CK and CD133 in primary lung adenocarcinoma patients[J].J Third Mil Med Univ,2017,39(20):2004-2009.
点击复制

Cytokeratin和CD133在肺腺癌患者外周血中的联合检测及临床病理分析(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
39卷
期数:
2017年第20期
页码:
2004-2009
栏目:
临床医学
出版日期:
2017-10-30

文章信息/Info

Title:
Combined detection and clinical pathological analysis of peripheral blood CK and CD133 in primary lung adenocarcinoma patients
作者:
刘鑫王一星李冠宏束金华张鹏博徐文漭赵玺龙
成都军区昆明总医院:心胸外科,病理实验科;云南省第二人民医院急诊科;云南宣威,云南省宣威市第一人民医院心胸外科
Author(s):
LIU Xin WANG Yixing LI Guanhong SHU Jinhua ZHANG Pengbo XU Wenmang ZHAO Xilong

Department of Cardiothoracic Surgery, Department of Pathology, Kunming General Hospital of Chengdu Military Command, Kunming,Yunnan Province, 650032; Department of Emergency, Second People’s Hospital of Yunnan Province,Kunming,Yunnan Province, 650032; Department of Cardiothoracic Surgery, First People’s Hospital of Xuanwei,Xuanwei, Yunnan Province, 655400, China

关键词:
肺腺癌循环肿瘤细胞CD133外周血预后指标
Keywords:
primary lung adenocarcinoma circulating tumor cells CD133 peripheral blood prognostic marker
分类号:
R341; R446.11; R734.2
文献标志码:
A
摘要:

目的     联合检测肺腺癌患者外周血中细胞角蛋白(cytokeratin,CK,肺腺癌循环肿瘤细胞阳性)和CD133基因(肺癌干细胞标志物)的表达,探讨二者在评估肺腺癌预后的临床价值。方法     选取2014年6月至2016年6月昆明总医院心胸外科和宣威市第一人民医院心胸外科的178例未化疗的肺腺癌手术患者,中位年龄59岁,其中男性78例,女性100例。收集患者术前外周血标本10 mL,细胞块法和CK(免疫细胞化学法)用于检测CTC,PCR法用于检测CD133表达。免疫组化法检测肺腺癌组织中CK、Vimentin(Vim)、TTF-1、Ki-67、CD133的表达,并分析与外周血CK和CD133表达的关系。根据外周血CK和CD133的检测结果,将病例分为CK/CD133双阳性组和非双阳性组,统计学分析两组间临床病理因素的差异。结果     178例肺腺癌患者外周血CTC(CK阳性)的检出率为48.3%(86/178),与癌组织中Ki-67、Vim表达显著正相关(P<0.05);外周血的CD133阳性表达率为66.9%(119/178),与癌组织Vim、CD133表达显著正相关(P<0.05);外周血CK/CD133双阳组53例(29.8%),双阳组淋巴结转移率显著增高,肺腺癌组织学分化级别显著降低,临床分期显著提高,转移率显著增高(P<0.05)。结论     肺腺癌患者外周血中CK与CD133双阳性表达提示外周血存在干性特征的循环肿瘤细胞,表明预后不良,联合检测CK与CD133可用于肺腺癌患者预后监测和指导治疗。

Abstract:

Objective    To investigate the combined detection of cytokeratin(CK) and CD133 in peripheral blood of patients with primary lung adenocarcinoma and its clinical significance as a prognostic marker. Methods    Totally 178 patients with primary lung adenocarcinoma who were admitted for the first time to Kunming General Hospital and First People’s Hospital of Xuanwei between June 2014 and June 2016 were included in this study(78 males and 100 females at their median age of 59 years).  Peripheral blood of 5 mL were enriched for preparing cell block and then detected for CK to label circulating tumor cells (CTCs). DNA was extracted from the other 5 mL peripheral blood for detecting expression of CD133 gene by PCR. The relations between clinicopathologic characteristics of lung cancer patients with the positive expression of CK and CD133 were analyzed respectively. Immunohistochemical assay was used to detect CK, Vimentin(Vim), TTF-1, Ki-67 and CD133 in lung adenocarcinoma tissues, and the relation was analyzed between these immunohistochemical results and expression of CK and CD133 in peripheral blood. Results    Positive rate of CK(CTC)expression was 48.3% (86/178) in peripheral blood of patients with lung adenocarcinoma, and the expression of CK was associated with that of Ki67 and Vim in tumor tissue. The detection rate of CD133 gene in peripheral blood was 66.9%(119/178)and was associated with the expression levels of Vim and CD133 in tumor tissue. The number of CK/CD133 co-positive cases was 53. Co-positive expression of CK and CD133 was associated with the lymph node metastatic rate, clinical stages, degree of differentiation and metastasis rate(all P<0.05). Conclusion     Co-positive  expression of CK and CD133 in peripheral blood of patients with primary lung adenocarcinoma indicates the existence of stemness CTCs,  and suggests poor prognosis. Joint detection of CK and CD133 is useful for prognostic assessment and treatment guidance.

参考文献/References:

[1]SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2017[J]. CA Cancer J Clin, 2017, 67(1): 7-30. DOI: 10.3322/caac.21387.
[2]HANAGIRI T, BABA T, SO T, et al. Time trends of surgical outcome in patients with nonsmall cell lung cancer[J]. Journal of Thoracic Oncology, 2010, 5(6): 825-829.
[3]MOLINA JR, YANG P, CASSIVI SD, et al. Nonsmall cell lung cancer: epidemiology, risk factors,treatment, and survivorship[J]. Mayo Clin Proc, 2008, 83(5): 584-594.
[4]ZHOU L, DICKER D T, MATTHEW E, et al. Circulating tumor cells: silent predictors of metastasis[J]. F1000Res, 2017, 6: 1445. DOI: 10.12688/f1000redearch.11313.1.
[5]REYA T, MORRISON S J. CLARKE F, et al. Stem cells, cancer, and cancer stem cells[J]. Nature, 2001, 414(6859): 105-111.
[6]BURKERT J, WRIGHT N A, ALISON M R. Stem cells and cancer: an intimate relationship[J]. J Pathol, 2006, 209(3): 287-297. DOI: 10.1002/path.2016.
[7]LOBO N A, SHIMONO Y, QIAN D, et al. The biology of cancer stem cells[J]. Annu Rev Cell Dev Biol, 2007, 23: 675-699. DOI: 10.1146/annurev.cellbio.22.010305.104154.
[8]MENDOZA M, KHANNA C. Revisiting the seed and soil in cancer metastasis[J]. Int J Biochem Cell Biol, 2009, 41(2009): 1452-1462. DOI: 10.1016/j.biocel.2009.01.015.
[9]BRYAN C. BARNHAR1 M C S. Metastasis and stem cell pathways[J]. Cancer Metastasis Rev, 2007, 26(2): 261-271.
[10]KOREN A, MOTALN H, CUFER T. Lung cancer stem cells: a biological and clinical perspective[J]. Cell Oncol (Dordr), 2013, 36(4): 265-275. DOI:10.1007/s13402-0130141-9
[11]FEHM T, SOLOMAYER E F, MENG S, et al. Methods for isolating circulating epithelial cells and criteria for their classification as carcinoma cells[J]. Cytotherapy, 2005, 7(2): 171-185.DOI: 10.1080/14653240510027082.
[12]YIN A H,  MIRAGLIA S, ZANJANI E D, et al. AC133, a novel marker for human hematopoietic stem and progenitor cells[J]. Blood, 1997, 90(12): 5002-5012.
[13]WU H, QI XW, YAN GN et al. Is CD133 expression a prognostic biomarker of non-small-cell lung cancer? a systematic review and metaanalysis[J]. PLoS ONE, 2014, 9(6): e100168. DOI: 10.1371/journal.pone.0100168.
 [14]TIRINO V, CAMERLINGO R, FRANCO R, et al. The role of CD133 in the identification and characterisation of tumourinitiating cells in non-small-cell lung cancer[J]. Eur J Cardiothorac Surg, 36(2009): 446-453. DOI: 10.1016/j.ejcts.2009.03.063.
[15]TRAVIS W D, BRAMBILLA E, NOGUCHI M, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma[J]. J Thorac Oncol, 2011, 6(2): 244-285. DOI:10.1097/JTO.0b013e318206a221.
[16]CIANCIO N, GALASSO M G, CAMPISI R, et al. Prognostic value of p53 and Ki67 expression in fiberoptic bronchial biopsies of patients with nonsmall cell lung cancer[J]. Multidisciplinary Respiratory Medicine, 2012, 7(1): 29.
[17]MARCHETTI A, DEL GRAMMASTRO M, FELICIONI L, et al. Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing:toward a realtime liquid biopsy for treatment[J]. PLoS ONE, 2014, 9(8): e103883. DOI: 10.1371/journal.pone.0103883.
 [18]HANSSEN A, LOGES S, PANTEL K, et al. Detection of circulating tumor cells in nonSmall cell lung cancer[J]. Front Oncol, 2015, 5(207): 1-5. DOI: 10.3389/fonc.2015.00207.
[19]HOFMAN V, ILIE M I, LONG E, et al. Detection of circulating tumor cells as a prognostic factor in patients undergoing radical surgery for non-small-cell lung carcinoma: comparison of the efficacy of the CellSearch Assay? and the isolation by size of epithelial tumor cell method[J]. International Journal of Cancer, 2011, 129(7): 1651-60.DOI: 10.1002/ijc.25819.
[20]ZEPPERNICK F, AHMADI R, CAMPOS B, et al. Stem cell marker CD133 affects clinical outcome in glioma patients[J]. Clin Cancer Res, 2008, 14(1): 123-129. DOI: 10.1158/1078-0432.CCR-07-0932.
[21]WOO T, OKUDELA K, MITSUI H, et al. Prognostic value of CD133 expression in stage Ⅰ lung adenocarcinomas [J]. International Journal of Clinical and Experimental Pathology, 2011, 4 (1): 32-42.
[22]WEN L, CHEN X Z, YANG K, et al. Prognostic value of cancer stem cell marker CD133 expression in gastric cancer: a systematic review[J]. PLoS ONE, 2013, 8(3): e59154. DOI: 10.1371/journal.pone.0059154.

相似文献/References:

[1]张瑞萍,吴继华,黄英武,等.循环肿瘤细胞检测指导老年非小细胞肺癌个体化治疗1例[J].第三军医大学学报,2012,34(22):2248.
[2]齐晓伟,姜军,杨新华,等.乳腺癌循环肿瘤细胞与原发肿瘤临床病理特征关系的初步研究[J].第三军医大学学报,2009,31(09):850.
 QI Xiao-wei,JIANG Jun,YANG Xin-hua,et al.Circulating tumor cells and clinicopathologic characteristics of primary tumor of breast cancer patients: report of 128 cases[J].J Third Mil Med Univ,2009,31(20):850.
[3]李雪涛,陈芳琳,王欣欣,等.95D细胞转移相关基因在原发灶、循环肿瘤细胞和转移灶中的差异表达[J].第三军医大学学报,2011,33(10):980.
 Li Xuetao,Chen Fanglin,Wang Xinxin,et al.Differential expression of metastasis-associated genes in primary tumor, circulating tumor cells, and metastasis of human giant-cell lung cancer cell line 95D[J].J Third Mil Med Univ,2011,33(20):980.
[4]李世超,姜军,杨新华,等.乳腺癌分子分型与外周血循环肿瘤细胞相关性探讨[J].第三军医大学学报,2012,34(10):1006.
 Li Shichao,Jiang Jun,Yang Xinhua,et al.Correlation between molecular subtypes and circulating tumor cells in breast cancer[J].J Third Mil Med Univ,2012,34(20):1006.
[5]王明浩,杨新华,张毅,等.乳腺癌外周血循环肿瘤细胞变化与新辅助化疗效果的关系[J].第三军医大学学报,2013,35(11):1148.
 Wang Minghao,Yang Xinhua,Zhang Yi,et al.Relationship of peripheral blood circulating tumor cells with therapeutic effect of neoadjuvant chemotherapy in breast cancer: report of 70 cases[J].J Third Mil Med Univ,2013,35(20):1148.
[6]王力伟,周晓洲,陈志文,等.膀胱癌循环肿瘤细胞NANOG基因的表达与临床特征相关性的初步研究[J].第三军医大学学报,2018,40(08):711.
 WANG Liwei,ZHOU Xiaozhou,CHEN Zhiwen,et al.Correlation of Nanog expression in circulating tumor cells with clinical characteristics of patients with bladder cancer[J].J Third Mil Med Univ,2018,40(20):711.
[7]杨松巍,王亮,李虎进,等.骨与软组织肉瘤患者检测循环肿瘤细胞及HOXB7基因表达的临床意义[J].第三军医大学学报,2020,42(10):1047.
 YANG Songwei,WANG Liang,LI Hujin,et al.Clinical significance of circulating tumor cells and their homeobox gene B7 expression in patients with bone and soft tissue sarcomas[J].J Third Mil Med Univ,2020,42(20):1047.

更新日期/Last Update: 2017-10-25